Prostate Cancer

A clinical trial will test a radiation regimen designed to preserve sexual function in men being treated for prostate cancer.

It's more than the beard. It's about men's health.

A high dose of precision radiation could drastically increase the survival rates of patients with metastatic cancer, and double the time patients live without cancer growth, according to study results presented at the 60th Annual Meeting of the American Society for Radiation Oncology.

Although there is never the perfect time to have a risk-related discussion with a child, one clinical psychologist explains ways in which parents can approach the difficult topic.

A genetic counselor discussed the various hereditary breast and ovarian cancer syndrome-associated cancers among men and how to manage them at the FORCE Annual Meeting.

The FDA has granted the PARP inhibitor Rubraca (rucaparib) a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer (mCRPC) following at least one androgen receptor–directed therapy and taxane-based chemotherapy.

Here are the top 5 CURE stories for September 2018.

Prostate cancer is one of the most common cancers in males, with about one man in nine to be diagnosed during his lifetime, according to the American Cancer Society.

Family history was one indicator that a man should undergo periodic screening, but it wasn’t until a couple of decades ago that scientists confirmed a link between inherited mutations of the BRCA gene and the development of prostate cancer.

Here's how one expert decides on the next steps in treatment when a man with prostate cancer has a rising PSA and no visible metastases.

Take a look at the top five CURE stories of June 2018 in this video.

We've come a long way in determining which patients with prostate cancer to treat, but there is still more work that needs to be done.

There are some key discussions that men with metastatic prostate cancer should have with their health care providers.

It is important that advocacy organizations unify their message, says Mike Crosby, the founder of the Veterans Prostate Cancer Awareness group.

The FDA approved the Paxman Scalp Cooling System for patients with solid tumors who wish to prevent chemotherapy-related hair loss.

Over the past few decades, prostate cancer has become better understood and treated more effectively.

The Food and Drug Administration (FDA) approved a new formulation of Yonsa (abiraterone acetate) in combination with methylprednisolone as a treatment for men with metastatic castration-resistant prostate cancer (mCRPC), according to Sun Pharma, the company commercializing the treatment.

The group came together to discuss gaps in knowledge concerning the prostate cancer journey, including nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic disease.

As part of the Prostate Cancer Foundation’s first annual campaign, Kristen Bell selected two winners because of their ‘candor and honesty’ to be honored.

Women felt that they could not show emotions of fear or vulnerability in front of their husbands or children.

The Food and Drug Administration granted Xtandi (enzalutamide) a priority review to a supplemental new drug application for the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to the companies developing the drug, Pfizer and Astellas.

With just one catwalk, the Prostate Cancer Foundation brought together celebrities, fashion designers and a special patient advocate to raise awareness for prostate cancer.

The Food and Drug Administration (FDA) approved Erleada (apalutamide) for the treatment of patients who have nonmetastatic castration-resistant prostate cancer (CRPC). The drug is now the first FDA-approved treatment in this setting.

More than 12 percent of men with prostate cancer tested positive for hereditary mutations of cancer-causing genes, according to study results presented at the 2018 Genitourinary Cancers Symposium.

Janssen Biotech announced that the Food and Drug Administration has approved Zytiga (abiraterone acetate) in combination with prednisone for high-risk castration-sensitive prostate cancer.

A study of 1,334 men diagnosed with non-metastatic prostate cancer showed a significantly increased risk of recurrence in those who consumed more than four servings of whole milk per week.

The Virtual Environment Radiotherapy Training (VERT™) system, originally designed to teach medical students and physicians about administering radiation therapy, is being used to explain to people who have prostate cancer what their treatment will look like.

The FDA has granted a priority review to a new drug application (NDA) for apalutamide (ARN-509) for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to Janssen Biotech, the manufacturer of the next-generation oral androgen receptor inhibitor.